Medicare Registry Plan For Alzheimer’s Drugs Pairs CMS Web Portal With Health System Efforts

The Centers for Medicare and Medicaid Services is not letting go of its plan to allow Medicare coverage of Alzheimer’s drugs with traditional approvals only if patients are enrolled in a registry. But in a statement released on 1 June, the agency suggests the requirement won’t be too onerous because it has set up a web portal to support and facilitate data submission from clinicians.

“Medicare will cover drugs with traditional FDA approval when a physician and clinical team participates in the collection of evidence about how these drugs work in the real world, also known as a registry,” CMS says